文献速递眼底病与葡萄膜炎白内障与屈光手术

既往玻璃体腔注射治疗患者白内障手术并发症风险

Risk of Cataract Surgery Complications in Patients With Prior Intravitreal Injection Therapy.
PubMed 文献 · Am J Ophthalmol · 2025-01-16

基于TriNetX数据库的回顾性队列研究,比较既往20年内接受玻璃体腔注射(IVI)与无IVI患者在倾向评分匹配后的白内障手术并发症。匹配后两组各14,240例,IVI组90天内总体并发症发生率3.3%(447/13,719)高于对照组2.4%(340/13,945),RR 1.34(95%CI 1.16-1.54);视网膜脱离修复风险在30天和90天均升高。作者认为术前规划应考虑IVI治疗史。

要点

  • 匹配后IVI组90天内总体并发症发生率3.3%(447/13,719),对照组2.4%(340/13,945),RR 1.34(95%CI 1.16-1.54)。
  • IVI组视网膜脱离修复风险30天RR 1.84(95%CI 1.27-2.66),90天RR 2.05(95%CI 1.65-2.54)。
  • 糖尿病视网膜病变患者中,IVI与90天前部玻璃体切除率较高相关(RR 1.24;95%CI 0.85-1.79)。

核心结论

  • 既往接受IVI的患者白内障手术后并发症更多,主要表现为视网膜脱离。
  • 作者认为术前规划应考虑IVI治疗史。

研究设计与样本

  • 回顾性队列研究,使用TriNetX聚合研究网络。
  • 纳入白内障手术前20年内接受IVI治疗的患者,以倾向评分匹配(PSM)平衡人口学、全身及眼部合并症后与对照组比较。
  • 排除白内障手术前已行晶状体切除或平坦部玻璃体切除(PPV)的患者。

主要发现

  • PSM前,有IVI药物治疗者16,356例,无IVI者512,152例;PSM后两组各14,240例。
  • IVI组白内障手术后90天内总体并发症发生率3.3%(447/13,719),对照组2.4%(340/13,945),RR 1.34(95%CI 1.16-1.54)。
  • IVI组视网膜脱离修复风险30天RR 1.84(95%CI 1.27-2.66),90天RR 2.05(95%CI 1.65-2.54)。
  • IVI仅在糖尿病视网膜病变(DR)患者中与90天前部玻璃体切除率较高相关(RR 1.24;95%CI 0.85-1.79)。
  • 合并DR且接受IVI暴露的患者晶状体切除、视网膜脱离修复及二次手术更多。

临床怎么用

  • 作者认为术前规划应考虑IVI治疗史。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To compare cataract surgery complications in patients with and without prior intravitreal injection (IVI). DESIGN: A retrospective cohort study using the TriNetX aggregated research network. SUBJECTS: Patients with IVI therapy within twenty years of cataract surgery were compared to controls using propensity score matching (PSM) to balance for demographics, systemic, and ocular co-morbidities. Patients with lensectomy or pars plana vitrectomy (PPV) prior to cataract surgery were excluded. INTERVENTION: IVI within twenty years of cataract surgery. MAIN OUTCOME MEASURES: Rate of retinal detachment (RD), RD repair, anterior vitrectomy, retained lens, dislocated intraocular lens (IOL), secondary lens procedure, and endophthalmitis within 14, 30, and 90 days of cataract surgery. RESULTS: Prior to PSM, 16,356 and 512,152 patients did and did not, respectively, have IVI pharmacotherapy prior to cataract surgery. After PSM, both groups had 14,240 patients. A higher rate (RR 1.34; 95% CI:1.16-1.54) of aggregate complications within 90 days of cataract surgery was found in the group with prior IVI (447/13,719 = 3.3%) relative to controls (340/13,945=2.4%). The exposure group saw an increased risk of RD repair at 30 days (RR 1.84; 95% CI:1.27-2.66) and 90 days (RR 2.05; 95% CI:1.65-2.54). IVI was only associated with higher rates of anterior vitrectomy in patients with diabetic retinopathy (DR) at 90 days (RR 1.24; 95% CI:0.85-1.79). Patients with DR and IVI exposure had more lensectomies, RD repairs, and secondary procedures. CONCLUSIONS: Patients with prior IVI saw more complications following cataract surgery, primarily for RD. IVI treatment history should be considered in pre-operative planning.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Zhao CS, Chwialkowski K, Wai KM, et al. Risk of Cataract Surgery Complications in Patients With Prior Intravitreal Injection Therapy. Am J Ophthalmol. 2025. PMID: 39826858. doi:10.1016/j.ajo.2025.01.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。